Phase 3
Completed N=42
Dexamethasone for Post Uterine Artery Embolization Pain
Source: ClinicalTrials.gov NCT04655144 ↗Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcomePrimary: Pain Scores Using the VAS Questionnaire — 0.8; 1.3; 4; 6.1 score on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this research is to investigate if administration steroids (anti-inflammatory medication) via the uterine arteries during uterine fibroid embolization (A non surgical procedure for treating uterine fibroids by blocking their blood supply) can help reduce the pain, nausea, vomiting, and general feeling of weakness following the procedure.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Scores Using the VAS Questionnaire |
0.8; 1.3; 4; 6.1; 6; 6.3 | — |
| SECONDARY Severity of Post-embolization Syndrome Symptoms |
0; 0; 0.1; 0.2; 0.3; 0.4 | — |
| SECONDARY Change in Symptoms |
2.4; 2.3; 1.7; 1.8; 1.9; 1.9 | — |
| SECONDARY Change in Quality of Life |
5.2; 5.5; 2.5; 1.3 | — |
Eligibility Criteria
Inclusion Criteria
- Women who meet criteria to undergo uterine fibroid embolization for symptomatic fibroids.
Exclusion Criteria
- Currently pregnant or actively attempting to conceive
- Those deemed mentally impaired to make their own medical decisions
- Previous documented allergy to dexamethasone
- Those currently taking daily steroids for any reason
- Those with diabetes or deemed to be pre-diabetic
- Those with contraindications for angiography
- Prisoners
Data sourced from ClinicalTrials.gov (NCT04655144). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.